PFE•benzinga•
Pfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal
Summary
Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody SSGJ-707.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 20, 2025 by benzinga